Olmesartan medoxomil and Azulfidine drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Olmesartan medoxomil (olmesartan medoxomil) and Azulfidine (sulfasalazine). Common drug interactions include loss of consciousness among females and disseminated intravascular coagulation among males.

The phase IV clinical study analyzes what interactions people have when they take Olmesartan medoxomil and Azulfidine. It is created by eHealthMe based on reports of 28 people who take the same drugs from the FDA, and is updated regularly.

What is Olmesartan medoxomil?

Olmesartan medoxomil has active ingredients of olmesartan medoxomil. It is often used in high blood pressure. eHealthMe is studying from 15,240 Olmesartan medoxomil users. Check the latest studies of Olmesartan medoxomil.

What is Azulfidine?

Azulfidine has active ingredients of sulfasalazine. It is often used in rheumatoid arthritis. eHealthMe is studying from 7,997 Azulfidine users. Check the latest studies of Azulfidine.

On Jul, 15, 2026

28 people who take Olmesartan medoxomil and Azulfidine together, and have interactions are studied.

Olmesartan medoxomil and Azulfidine drug interactions.

What are the common drug interactions of Olmesartan Medoxomil and Azulfidine, by gender? *:

female:

Loss of consciousness
Drug rash with eosinophilia and systemic symptoms (adverse drug reactions with rash)
Pleurisy (inflammation of the pleurae, which causes pain when breathing)
Pneumonia
Pneumonia pneumococcal (pneumococcal pneumonia is a common but serious infection and inflammation of the lungs)
Renal impairment (severely reduced kidney function)
Skin ulcer
Blood creatinine increased
Demyelination (loss of the myelin covering of some nerve fibres resulting in their impaired function)
Diabetic ketoacidosis (diabetic ketoacidosis (dka) is high concentrations of ketone bodies)

male:

Disseminated intravascular coagulation (systemic activation of blood coagulation)
Septic shock (shock due to blood infection)
Herpes zoster
Iga nephropathy (kidney disease- condition prevents the kidneys from filtering waste)
Nephrotic syndrome (kidney disease with proteinuria, hypoalbuminemia, and oedema)
Portal vein thrombosis (venous thrombosis affecting the hepatic portal vein)
Abscess (pus)
Anal fistula infection
Bone marrow disorder
Bronchopulmonary aspergillosis (lung disorder caused by aspergillus fungi)

What are the common drug interactions of Olmesartan Medoxomil and Azulfidine, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

n/a

40-49:

n/a

50-59:

Drug rash with eosinophilia and systemic symptoms (adverse drug reactions with rash)
Human herpesvirus 6 infection

60+:

Disseminated intravascular coagulation (systemic activation of blood coagulation)
Septic shock (shock due to blood infection)
Herpes zoster
Iga nephropathy (kidney disease- condition prevents the kidneys from filtering waste)
Loss of consciousness
Nephrotic syndrome (kidney disease with proteinuria, hypoalbuminemia, and oedema)
Portal vein thrombosis (venous thrombosis affecting the hepatic portal vein)
Sinusitis (inflammation of sinus)
Abscess (pus)
Anal fistula infection

What are the existing conditions these people have? *

Osteoporosis (bones weak and more likely to break): 6 people, 21.43%
Insomnia (sleeplessness): 5 people, 17.86%
Gastric Ulcer (stomach ulcer): 5 people, 17.86%
Asthma: 4 people, 14.29%
Cerebral Infarction (less blood supply to brain resulting tissue damage): 3 people, 10.71%
Psoriasis (immune-mediated disease that affects the skin): 2 people, 7.14%
Polymyalgia Rheumatica (pain in many muscles): 2 people, 7.14%
Oral Herpes (viral infection of mouth): 2 people, 7.14%
Lumbar Spinal Stenosis (a medical condition in which the spinal canal narrows and compresses the spinal cord and nerves at the level of the lumbar bone): 2 people, 7.14%
Joint Pain: 2 people, 7.14%

* Approximation only. Some reports may have incomplete information.

Do you take Olmesartan medoxomil and Azulfidine?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously